Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) issued its earnings results on Monday. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.10, Zacks reports. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA traded up $0.28 during trading hours on Monday, reaching $5.55. The company’s stock had a trading volume of 106,051 shares, compared to its average volume of 286,101. Enanta Pharmaceuticals has a fifty-two week low of $4.09 and a fifty-two week high of $17.24. The stock has a market cap of $118.40 million, a PE ratio of -1.12 and a beta of 0.81. The company’s 50-day moving average is $5.66 and its two-hundred day moving average is $6.80.

Insider Activity at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly bought 45,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average cost of $5.69 per share, with a total value of $256,050.00. Following the transaction, the chief executive officer now owns 846,638 shares of the company’s stock, valued at $4,817,370.22. This represents a 5.61% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 13.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on ENTA shares. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 19th. Finally, JMP Securities reiterated a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.25.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.